Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 100 of 102, showing 5 Applications out of 510 total, starting on record 496, ending on 500

# Protocol No Study Title Investigator(s) & Site(s)

496.

ECCT/12/04/02   Short-course RPT/INH for latent TB in HIV-infected individuals
    A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection       
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

497.

ECCT/11/08/05   Rifapentine During Intensive Phase TB Treatment
        Evaluation of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis   
Principal Investigator(s)
1. Lena Matata
2. Kevin Cain
Site(s) in Kenya
KEMRI/CDC-KISUMU
 
View

498.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
View

499.

ECCT/10/05/02   AERAS-402
    A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter, Proof-of-concept Study to Evaluate the Safety and Efficacy of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis   
Principal Investigator(s)
1. Dr Videlis Nduba
2. Dr Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI-CDC
 
View

500.

ECCT/13/03/02   An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples
    An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project   
Principal Investigator(s)
1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI
Site(s) in Kenya
1. THIKA (Nairobi City county)
 
View